June Abadilla
Internal Medicine · Jackson, KYNPI 1811975683
Payments from drug & device makers
Across 479 payments — averaging $20.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Lilly USA, LLC$1K
- Boehringer Ingelheim$1K
- Novo Nordisk$771
- GSK$753
- Electromed, Inc.$584
- plus $3K from 26 others
What the payments were for
- Food & beverage$9,63999%
- Education$1341%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 65 | $1,986 |
| Lilly USA, LLC | 73 | $1,285 |
| Boehringer Ingelheim | 54 | $1,201 |
| Novo Nordisk | 50 | $771 |
| GSK | 49 | $753 |
| Electromed, Inc. | 26 | $584 |
| Grifols USA, LLC | 21 | $479 |
| Bayer | 20 | $389 |
| Sanofi | 11 | $296 |
| Philips North America LLC | 16 | $253 |
| Amgen | 12 | $232 |
| Vifor Pharma, Inc. | 9 | $198 |
| Baxter Healthcare | 9 | $168 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $162 |
| Verona Pharma, Inc. | 8 | $161 |
| Regeneron Healthcare Solutions, Inc. | 6 | $158 |
| Insmed, Inc. | 10 | $149 |
| CSL Behring | 3 | $98 |
| Dexcom, Inc. | 3 | $83 |
| Pfizer | 4 | $60 |
| AbbVie | 2 | $54 |
| Lexicon Pharmaceuticals, Inc. | 3 | $45 |
| Xeris Pharmaceuticals, Inc. | 2 | $37 |
| Mylan Specialty L.p. | 3 | $37 |
| Abbott | 2 | $32 |
| Phadia US Inc. | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Bardy Diagnostics, Inc. | 2 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
| Mallinckrodt Enterprises LLC | 1 | $12 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,773 in reported general payments places this provider in the 90th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 298 | $383,595 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 28 | $315,452 |
| OzempicSemaglutide | 180 | $250,519 |
| JardianceEmpagliflozin | 156 | $214,669 |
| EliquisApixaban | 137 | $163,436 |
| ZemairaAlpha-1-Proteinase Inhibitor | 14 | $152,045 |
| TrulicityDulaglutide | 108 | $151,718 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 124 | $139,596 |
| FarxigaDapagliflozin Propanediol | 98 | $123,207 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 106 | $105,434 |
| LinzessLinaclotide | 67 | $77,512 |
| JanuviaSitagliptin Phosphate | 60 | $66,750 |
| RybelsusSemaglutide | 27 | $50,954 |
| TradjentaLinagliptin | 40 | $49,642 |
| LeqvioInclisiran Sodium | 13 | $42,921 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,285 | $535,313406 claims |
| Novo NordiskOzempic, Rybelsus, Wegovy | $771 | $315,696218 claims |
| Grifols USA, LLCProlastin C | $479 | $315,45228 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Spiriva Respimat | $1,201 | $309,627249 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Lokelma, Nexium | $1,986 | $296,030327 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $753 | $174,249174 claims |
| PfizerEliquis | $60 | $163,436137 claims |
| CSL BehringZemaira | $98 | $152,04514 claims |
| AbbVieLinzess | $54 | $77,51267 claims |
| Johnson & JohnsonXarelto | $13 | $27,98720 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $162 | $4,54413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Jackson
- Mark AdamsLondon$15.4M
- Matthew WenkerErlanger$12.8M
- Jason ChesneyLouisville$6.3M
- Neil FarrisLexington$3M
- David JohnsonOwensboro$787K
- Hollis ClarkMurray$780K
- Fares KhaterWhitesburg$412K
- Christopher PhillipsPaducah$315K
- Cynthia Bowman-StroudPaducah$234K
- Bernard BuchananOwensboro$224K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.